Inscriere cercetatori

Site nou !

Daca nu va puteti recupera parola (sau aveti alte probleme), scrieti-ne la pagina de contact. Situl vechi se gaseste la adresa old.ad-astra.ro

Facebook

Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.

Domenii publicaţii > Ştiinţe medicale + Tipuri publicaţii > Articol în revistã ştiinţificã

Autori: Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M, Andrieu JM, Oudard S.

Editorial: Elsevier, Eur Urol, 55(5), p.January 13, 2009.

Rezumat:

Abstract
We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10mg/kg) in combination with sunitinib 25–50mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab–sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile.

Cuvinte cheie: bevacizumab, cancer renal, tratament de salvare, sunitinib // Bevacizumab, Renal cell carcinoma, Salvage therapy, Sunitinib

URL: http://www.europeanurology.com/article/S0302-2838(09)00003-7/abstract